Valued at $555.0M at its early-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Bambusa Therapeutics: the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Bambusa Therapeutics funding history
4 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2025 | Early Stage VC (Series A2) | $40.0M | ▮ | ▮ |
| Feb 2025 | Early Stage VC (Series A) | $88.9M | ▮ | ▮ |
| Jun 2024 | Early Stage VC | $9.0M | ▮ | ▮ |
| Jun 2024 | Early Stage VC | $5.1M | ▮ | ▮ |
Membership and data by Private Market View
Bambusa Therapeutics valuation
Bambusa Therapeutics was valued at $555 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Bambusa Therapeutics raised?
Bambusa Therapeutics has raised $143 million across 4 recorded rounds since 2024. The largest was a $9 million early-stage round in Jun 2024; the most recent was a $40 million Series A2 in Oct 2025.
Bambusa Therapeutics has filed 3 Form Ds with the SEC, most recently in Feb 2025 ($53.3 million sold to 16 investors).
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: VeraDermics (NYS: MANE) ($596 million), Superluminal Medicines ($576 million) and Strand Therapeutics ($571 million).
How Bambusa Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Bambusa Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →
Frequently asked about Bambusa Therapeutics
- What is Bambusa Therapeutics worth?
- Bambusa Therapeutics is valued at $555.0M as of Oct 2026. Valued at $555.0M at its early-stage round, Oct 2025. Nothing has traded since.
- How much has Bambusa Therapeutics raised?
- Bambusa Therapeutics has raised $143.0M in total funding across 4 recorded rounds.
- When did Bambusa Therapeutics last raise?
- Bambusa Therapeutics last raised in Oct 2025 (Early Stage VC (Series A2)), raising $40.0M.